This innovation, which has obtained a CE marking, has been carried out by GENOMICA's R&D team in
The new qCOVID-19 Respiratory COMBO test has now successfully completed trials carried out with nasopharyngeal samples from patients with additional/other respiratory infections at the 'Hospital Universitario La Paz', the 'Hospital Clinico Universitario de
GENOMICA's test obtained sensitivities of over 95% and specificities of over 99.7%. The Company's diagnostic PCR kit has therefore proven to be highly sensitive and specific in differentiating and detecting respiratory viruses, including SARS-CoV-2, even allowing for the detection of asymptomatic cases.
This new test, is PCR based, a reference method for virus detection that makes it possible to differentiate SARS-CoV-2 virus, which is the cause of the current COVID-19 pandemic, from other viruses. This is clinically important, due to the similarity of the symptoms caused by these common respiratory diseases: Influenza A and B, as well as infections caused by RSV. A rapid and accurate diagnosis can be done within hours, which ultimately allows doctors to classify patients and determine the most appropriate treatment and isolation measures for each case.
The product is now commercially available and is compatible with Real Time PCR or qPCR technology, a widely used technology for diagnosis in hospitals, health centers or diagnostics laboratories.
GENOMICA has commercial agreements in over 20 countries around the world.
The Company remains committed to supplying Spanish institutions. Since the launch of the first COVID-19 PCR kit with the CE marking up to today, thousands of patients have been tested for SARS-CoV-2 with GENOMICA's kits, which are manufactured at its facilities located in
Coronaviruses are an extended family of viruses that can cause the common cold, other more serious diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
INGESA Framework Agreement
GENOMICA is one of the awarded companies in the
The Company makes its qCOVID-19 Respiratory COMBO test available for sale exclusively to hospitals and professional molecular biology laboratories and requires instrumentation and qualified personnel.
About
Headquartered in
About GENOMICA
GENOMICA is highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in
Contact:
Tel: + 34609493127
Email: aortin@pharmamar.com
(C) 2020 Electronic News Publishing, source